WO2008069262A1 - 安定性が改善されたフィルムコーティング製剤 - Google Patents
安定性が改善されたフィルムコーティング製剤 Download PDFInfo
- Publication number
- WO2008069262A1 WO2008069262A1 PCT/JP2007/073547 JP2007073547W WO2008069262A1 WO 2008069262 A1 WO2008069262 A1 WO 2008069262A1 JP 2007073547 W JP2007073547 W JP 2007073547W WO 2008069262 A1 WO2008069262 A1 WO 2008069262A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- film coating
- film
- compound
- general formula
- pharmacologically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Definitions
- the film layer contains one or more film coating bases selected from polybutanolol, sodium carboxymethylcellulose and pullulan in the film layer Excellent film coating on the formulation.
- Patent Document 1 The compound having the above general formula (I) or a pharmacologically acceptable salt thereof is known as a compound having an inhibitory action on platelet aggregation (Patent Document 1 or 2).
- Patent Documents 2, 3, 4 and 5 disclose compounds having the above general formula (I) or their pharmacologically acceptable properties.
- the roulose sodium itself is not specifically described.
- Patent Documents 2, 4 and 5 only describe that a coating can be applied as necessary. Specifically, polybutyl alcohol, carboxymethyl cellulose sodium or pullulan is specifically described. Not used in formulation examples. Further, the above patent document contains a poly (alcohol), carboxymethyl cellulose sodium or pullulan as a film coating base in a preparation containing the compound having the above general formula (I) or a pharmacologically acceptable salt thereof. Improving the stability of the formulation Neither listed nor suggested.
- Patent Document 1 JP-A-6-41139
- Patent Document 2 Japanese Patent Laid-Open No. 2002-145883
- Patent Document 3 JP-A-10-310586
- Patent Document 4 Japanese Patent Laid-Open No. 2003-246735
- Patent Document 5 Japanese Unexamined Patent Application Publication No. 2004-51639
- An object of the present invention is to provide a pharmaceutical composition excellent in storage stability, containing a compound having the above general formula (I) or a pharmacologically acceptable salt thereof.
- the present invention contains a compound having the above general formula (I) or a pharmacologically acceptable salt thereof in a formulation, and one kind selected from polybutal alcohol, carboxymethylcellulose sodium and pullulan in a film layer. Or a film coating preparation (especially a film coating preparation for the prevention or treatment of thrombosis or embolism) containing two or more film coating bases, and a film coating preparation (especially for thrombosis or embolism).
- the present invention provides:
- a compound having the above general formula (I) or a pharmacologically acceptable salt thereof is contained in the formulation, and polybulal alcohol, sodium carboxymethyl cellulose and Film coating formulation containing one or more film coating bases selected from pullulan
- the compound having the above general formula (I) or a pharmacologically acceptable salt thereof is contained in the formulation, and the film layer is selected from polybutanol, sodium carboxymethylcellulose and pullulan 1 It is possible to provide a film coating preparation having excellent storage stability, which contains two or more kinds of film coating bases.
- the film coating preparation of the present invention is, for example, a therapeutic and / or prophylactic agent for thrombosis or embolism (preferably, embolism). Is effective).
- a compound having the above general formula (I) or a pharmaceutically acceptable salt thereof, that is, an active ingredient of the film coating preparation of the present invention, that is, 2-acetoxy-5 ( ⁇ -cyclopropenocarbonylcarbonyl 2 fluorobenzyl) 4, 5, 6, 7 Tetrahydroceno [3,2-c] pyridine or a pharmacologically acceptable salt thereof is a known compound, and is a method described in JP-A-6-41139 or JP-A-2002-145883. Can be manufactured.
- the "pharmacologically acceptable salt” of the present invention includes, for example, a hydrohalide salt such as hydrofluoride, hydrochloride, hydrobromide, or hydroiodide; nitrate Inorganic acid salts such as perchlorate, sulfate or phosphate; lower alkyl sulfonates such as methane sulfonate, trifluoromethane sulfonate or ethane sulfonate; benzene sulfonate or ⁇ toluene Aryl sulfonates such as sulfonates; organics such as acetate, malate, fumarate, succinate, succinate, ascorbate, tartrate, oxalate or maleate Acid salts; or amino acid salts such as glycine salt, lysine salt, arginine salt, ornithine salt, glutamate salt or aspartate.
- a Gen hydrobromide or an organic acid salt more
- the film coating base in the present invention is one or two or more selected from polybulal alcohol, sodium carboxymethylcellulose or pullulan, and preferably polybulal alcohol or sodium carboxymethylcellulose.
- the lower limit of the content of the coating base in the film layer is usually 20% (w / w), preferably 30% (w / w), and more preferably 40% (w
- the upper limit is usually 100% (w / w), preferably 90% (w / w), and more preferably 70% (w / w)
- coating bases can be blended in the film layer as necessary.
- the kind of such coating base is not particularly limited, and can be appropriately selected by those skilled in the art.
- Such coating bases include, for example, polybulurpyrrolidone (PVP), methylcellulose, ethinoresenorelose, hydroxypropenoresenorelose (HPC), hydroxypropinolemethylcellulose (HPMC), dextrin, manoletodextrin, lactose
- PVP polybulurpyrrolidone
- HPC hydroxypropenoresenorelose
- HPMC hydroxypropinolemethylcellulose
- dextrin manoletodextrin
- lactose lactose
- the D Mannitho Nonolere Populi riburua arru coco rupo polima rimmer, methacryloyl acrylate cocopo poly limmer, amimino noaralkyl methole octyl rilre This includes the
- the pharmaceutical preparations of the film mucocoatings according to the present invention are prepared according to the appropriate pharmacological physics according to the necessity.
- Tolerable excipients that are tolerated from a scientific viewpoint Lubricants, Binders, Emulsifiers, Stable stabilizers, It can be made with a flavoring and flavoring agent and / or an additive additive such as a dilute diluent and the like. .
- Examples of the “shaped excipient” that can be used include, for example, lactose, sugar, white sugar, bududo sugar, Sugarcane-induced conductors such as mammoninitool, sosorubibitol;; corn worms; , ⁇ --Dedenpunun, or Dedenpsun-induced conductors such as Dedexquist Trilin ;; Secerro Loro such as crystallized cerel loose Soot-inducing conductor ; Araarabibia agoumum ; Or, organic organic-based excipients such as Dedexkistratran, etc .: or some !!
- the dosage form is one or more selected from a selcerolose-inducing conductor and a sugar-inducing conductor.
- lactose sugar More preferably and suitably, lactose sugar, mamanninitotol and ligation
- One or more of the excipients selected from the crystalline cerel lorose, and most preferably, most preferably, lactose It is sugar and / or crystallized cerel lorose. .
- the "sliding agent" to be used for example, for example, for example, stetea allyl phosphate ;; Rustiumumum or a metal metal salt of steteaarylphosphate, such as magnegnenesium stetearate, phosphate; Wabiekuxus, such as the Vibe's Waxkussu or young Gegeyi ;; boroboric acid ;; aazidipypic acid ;; sulfur such as natotrilium sulfate Sulfate salt ;; Gumlicorcolic acid ;; Fumaric acid; Fustemalic acid stetearialyryl lunatotriliumum ;; Sucrose sugar fat fatty acid estesterol; DD ,, LL—loroicincin ;; lauraurilyl sulfate, sodium natotrilium sulfate Anhydrous silicic acid or a silicic acid such as hydrated silicic acid hydrate; or or the above-
- binding agent for example, hydridoxoxy propyl pisel lucerulose, hydrido Loxixip Mouth Pipirul Memethicyl Luce Cellulolose, Popoliribubirupiropiroleridone, Poplarie Ethylenic Linglicorikol, or or Examples of compounds such as compound compounds similar to that of the dosage form can be listed here, and preferably, hydroxypropyl propyl.
- the "milk emulsifying agent" used for use is, for example, bevennt tonaitite or bibigagamum.
- Una Cocororoid Clay such as magnesium hydroxide or aluminum hydroxide; anionic surfactants such as sodium lauryl sulfate or calcium stearate; cationic surfactants such as benzalkonium chloride; or polyoxyethylene
- Nonionic surfactants such as alkyl ethers, polyoxyethylene sorbitan fatty acid esters or sucrose fatty acid esters can be mentioned.
- Examples of the "stabilizer” used include para-benzoic acid esters such as methylparaben or propylparaben; alcohols such as chlorobutanol, benzyl alcohol or phenylethyl alcohol; benzalkonium chloride; And phenols such as thiol or talesol; thimerosal; dehydroacetic acid; or sorbic acid.
- sweeteners such as sodium saccharin or aspartame
- acidulants such as citrate, malic acid or tartaric acid
- menthol lemon or orange. And the like.
- the amount of the compound having the above general formula (I) or a pharmacologically acceptable salt thereof in the total amount of the film coating preparation is not particularly limited, but for example, 1. It is preferable to add 0 to 30.0% by weight (preferably 1.3 to 20.0% by weight).
- the amount of the additive in the total amount of the film coating preparation is not particularly limited.
- the excipient may be 10.0 to 93.5 wt% (preferably based on the total weight of the film coating preparation). 40.0 to 90.0% by weight), lubricant 0.5 to 5.0% by weight (preferably 0.5 to 3.0% by weight), and binder 0.0 to 15.0% by weight (preferably 2.5 to 10.0% by weight) is preferably blended.
- Examples of the film coating preparation in the present invention include solid preparations such as tablets, capsules, powders, fine granules, granules or lozenges, and tablets are preferred.
- the "direct tableting method” is a method of preparing a raw material powder by direct compression molding.
- the "dry granulation method” is a method in which a raw material powder is compression-molded into slugs or sheets and crushed and divided by an appropriate method to prepare a formulation. These methods are the Theory and Practice of Industrial Pharmacy (Third Edition) (Leon Lachman et al .: LEA & FEBIGER 1986) or Pharmaceutical Dosage Forms: Tablets volume 1 (Second Edition) (Herbert A. Lieberman et al .: MARCEL DEKKER INC. 1989 ).
- the granulation refers to an operation of producing granules having a substantially uniform shape and size from raw materials such as powder, lump, solution or molten liquid. The final granule, powder, fine granule, etc. There are granulations that produce products and granulations that produce intermediate products such as tablets or capsules.
- the compression molding process is a process of applying pressure to the raw material powder with a mechanical force to turn the raw material powder into a lump.
- apparatuses used include a rotary tablet machine (Kikusui Seisakusho Co., Ltd.). Dry granulators (manufactured by Freund Sangyo Co., Ltd., Turbo Kogyo Co., Ltd., Kurimoto Kyosho Co., Ltd.) Matsubo, Nippon Dananulator, Fuji Powdere, etc.).
- the crushing / splitting process is a process of crushing the lump formed in the compression molding process to an appropriate size with a knife / cutter, etc.
- equipment used include a power mill, a fit mill, and a fiore.
- crushing machines such as Comil or granulators (Fuji Baudal, Deoksugaku Kogyo, Baurek, etc.) can be cited.
- the granulated product thus obtained is sized to a desired particle size, and can be made into a preparation in the form of a powder, fine granule or granule. These preparations can be filled into capsules to form capsules, or further, disintegrating agents and / or lubricants can be added as necessary, and compressed into tablets using a tableting machine. It can also be. Operations such as mixing or granulation are all widely used in the field of pharmaceutical technology, and those skilled in the art can appropriately perform them. And force S.
- the film coating preparation of the present invention may further include one of plasticizers, excipients, lubricants, masking agents, coloring agents, preservatives and the like in an amount usually used in the formulation, if necessary. Or more additives can be included.
- plasticizer that can be used in the present invention is not particularly limited, and can be appropriately selected by those skilled in the art.
- plasticizers include propylene glycol, polyethylene glycol, polypropylene glycol, glycerin and sorbitol, glycerin triacetate, jetyl phthalate and triethyl taenoate, lauric acid, sucrose, dextrose, sorbitol, triacetin, and acetyl.
- examples thereof include triethyl citrate, triethyl citrate, tributyl citrate, and acetyl tilpyl citrate.
- Examples of the concealing agent that can be used in the present invention include titanium oxide.
- Examples of the colorant that can be used in the present invention include titanium oxide, iron oxide, ferric oxide, yellow ferric oxide, and yellow No. 5 aluminum lake talc.
- Examples of the preservative that can be used in the present invention include nitrogen and the like.
- the film coating preparation prepared by this method is prepared by using a film coating solution containing one or more film coating bases selected from polybulal alcohol, sodium carboxymethyl cellulose and pullulan as a tablet or raw material. It is possible to obtain power S by spraying on the object to be coated such as medicine.
- the object to be coated may be sub-coated if desired.
- the film coating solution is obtained by suspending or dissolving in water one or more film coating bases selected from polybutanolol, sodium carboxymethylcellulose, and pullulan, and the above-mentioned additives that are optionally blended.
- the spraying of the film coating solution may be performed by a known method such as using a commercially available film coating machine.
- Film coating has a lower limit on the uncoated tablet weight, preferably 3% (w / w), more preferably 4.5% (w / w), especially The upper limit is preferably 6% (w / w), preferably 50% (w / w), more preferably 20% (w / w).
- the film coating preparation of the present invention obtained by force can be administered in the same manner as a normal preparation.
- the dose of the compound having the above general formula (I) or a pharmacologically acceptable salt thereof, which is an active ingredient of the film coating preparation of the present invention is such as drug activity, patient symptom, age or body weight. It can vary depending on various conditions. In the case of oral administration, the dose is usually 1 day for adults, 0. Olmg (preferably lmg) as the lower limit and 200 mg (preferably lOOmg) as the upper limit. Can be administered.
- Compound A used in the examples is a compound having the above formula (la).
- the obtained mixed powder was tableted with a rotary tableting machine at a tableting pressure of 6.9 kN so that the tablet mass was about 10 mg.
- the obtained uncoated tablets were spray-coated with a coating solution composed of sodium carboxymethylcellulose 5% (w / w) and water in a pan coating machine to obtain tablets containing the test compound.
- Table 1 shows the results of a stability test performed on the obtained tablets.
- the obtained mixed powder was tableted with a rotary tableting machine at a tableting pressure of 6.9 kN so that the tablet mass was about 10 mg.
- the obtained uncoated tablets are coated with OPA DRY AMB 31W48994 (manufactured by Nippon Colorcon Co., Ltd.) and water coating solution, which is mainly composed of polybulu alcohol. Tablets containing the compound were obtained.
- Table 1 shows the results of a stability test conducted on the obtained tablets.
- the obtained mixed powder was tableted with a rotary tableting machine at a tableting pressure of 6.9 kN so that the tablet mass was about 10 mg.
- the obtained uncoated tablets were spray-coated with a coating solution consisting of hydroxypropylmethylcellulose, lactose, titanium oxide, triacetin and water in a pan coating machine to obtain tablets containing test compounds.
- Table 1 shows the results of a stability test conducted on the obtained tablets.
- the tablets obtained in Examples 1 and 2 and the tablet obtained in Comparative Example 1 were placed in a brown glass bottle and allowed to stand in a sealed state at 60 ° C. After 3 weeks, the active ingredients in the test tablets (general formula ( The content of the compound having I) was determined by high performance liquid chromatography.
- the measurement conditions for high-speed liquid chromatography are as follows.
- the compound having the above general formula (I) or a pharmacologically acceptable salt thereof is contained, and the film layer contains one or more kinds selected from polybutyl alcohol, sodium carboxymethylcellulose and pullulan.
- a film coating preparation containing a film coating base and excellent in storage stability can be obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020097011282A KR101665705B1 (ko) | 2006-12-07 | 2007-12-06 | 안정성이 개선된 필름 코팅 제제 |
CA2671975A CA2671975C (en) | 2006-12-07 | 2007-12-06 | Film-coated preparation having improved stability |
CN2007800449606A CN101594863B (zh) | 2006-12-07 | 2007-12-06 | 具有改进稳定性的涂膜制剂 |
BRPI0719395A BRPI0719395C1 (pt) | 2006-12-07 | 2007-12-06 | tablete revestido de filme |
JP2008548325A JPWO2008069262A1 (ja) | 2006-12-07 | 2007-12-06 | 安定性が改善されたフィルムコーティング製剤 |
EP07850163A EP2100606A4 (en) | 2006-12-07 | 2007-12-06 | COATED PREPARATION OF A FILM HAVING IMPROVED STABILITY |
US12/312,969 US20090291138A1 (en) | 2006-12-07 | 2007-12-06 | Film-coated preparation having improved stability |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006330371 | 2006-12-07 | ||
JP2006-330371 | 2006-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008069262A1 true WO2008069262A1 (ja) | 2008-06-12 |
Family
ID=39492140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/073547 WO2008069262A1 (ja) | 2006-12-07 | 2007-12-06 | 安定性が改善されたフィルムコーティング製剤 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20090291138A1 (ja) |
EP (1) | EP2100606A4 (ja) |
JP (1) | JPWO2008069262A1 (ja) |
KR (1) | KR101665705B1 (ja) |
CN (1) | CN101594863B (ja) |
BR (1) | BRPI0719395C1 (ja) |
CA (2) | CA2671975C (ja) |
TW (1) | TWI442947B (ja) |
WO (1) | WO2008069262A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010094471A1 (en) * | 2009-02-17 | 2010-08-26 | Krka, D. D., Novo Mesto | Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation |
WO2011015599A1 (de) | 2009-08-07 | 2011-02-10 | Ratiopharm Gmbh | Prasugrel in nicht-kristalliner form und pharmazeutische zusammensetzung davon |
WO2011052500A1 (ja) * | 2009-10-28 | 2011-05-05 | 第一三共株式会社 | ワックス安定製剤 |
WO2011052499A1 (ja) * | 2009-10-28 | 2011-05-05 | 第一三共株式会社 | 貯蔵安定性が改善された医薬組成物 |
WO2011065551A1 (ja) * | 2009-11-30 | 2011-06-03 | 東レ株式会社 | 固形製剤用のフィルムコーティング剤及びこれを用いた固形製剤 |
WO2011098536A1 (en) | 2010-02-11 | 2011-08-18 | Ratiopharm Gmbh | Prasugrel in micronized, crystalline form and pharmaceutical composition thereof |
US8900606B2 (en) | 2008-12-25 | 2014-12-02 | Toray Industries, Inc. | Methods of applying coating materials for solid medicines |
US9034860B2 (en) | 2006-12-07 | 2015-05-19 | Daiichi Sankyo Company, Limited | Pharmaceutical composition containing low-substituted hydroxypropyl cellulose |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI428151B (zh) * | 2006-12-07 | 2014-03-01 | Daiichi Sankyo Co Ltd | 含有甘露醇或乳糖之固形製劑 |
US20100280064A1 (en) * | 2006-12-07 | 2010-11-04 | Tomoyuki Watanabe | Pharmaceutical composition having improved storage stability |
DE112009000268T5 (de) | 2008-02-06 | 2011-06-01 | Helm Ag | Prasugrel-Salze mit verbesserten Eigenschaften |
TR201007926A1 (tr) * | 2010-07-19 | 2012-02-21 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Prasugrel tablet formülasyonları. |
TR201005900A1 (tr) * | 2010-07-19 | 2012-02-21 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Geliştirilmiş stabiliteye sahip prasugrel granülleri. |
EP2409685A3 (en) * | 2010-07-19 | 2012-02-01 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orally-disintegrating formulations of prasugrel |
TR201006802A1 (tr) * | 2010-08-17 | 2012-03-21 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Prasugrelin oral yolla dağılan formülasyonları. |
AR083711A1 (es) | 2010-11-17 | 2013-03-20 | Gilead Sciences Inc | Compuestos heterociclicos utiles en el tratamiento de la hepatitis c |
JP5860480B2 (ja) | 2011-01-11 | 2016-02-16 | キャプシュゲル・ベルジウム・エヌ・ヴィ | プルランを含む新しい硬カプセル |
RS54207B1 (en) | 2011-11-16 | 2015-12-31 | Gilead Pharmasset Llc | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS |
CZ2011872A3 (cs) | 2011-12-22 | 2013-07-03 | Zentiva, K.S. | Farmaceutická formulace prasugrelu hydrobromidu |
US8603537B2 (en) | 2012-04-02 | 2013-12-10 | Egis Pharmaceuticals Plc | Prasugrel containing quickly released stable oral pharmaceutical compositions |
ES2792503T3 (es) | 2013-08-27 | 2020-11-11 | Gilead Pharmasset Llc | Formulación combinada de dos compuestos antivirales |
WO2015030854A1 (en) * | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
CN103845302B (zh) * | 2014-03-24 | 2016-03-30 | 江苏知原药业有限公司 | 一种性能优异的托法替尼的片剂 |
TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
US11576870B2 (en) | 2017-04-14 | 2023-02-14 | Capsugel Belgium Nv | Pullulan capsules |
CN110678555B (zh) | 2017-04-14 | 2023-10-13 | 比利时胶囊公司 | 制作普鲁兰的方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4851777A (ja) * | 1971-10-30 | 1973-07-20 | ||
JPS5942325A (ja) * | 1982-09-03 | 1984-03-08 | Dai Ichi Seiyaku Co Ltd | コ−テイング用組成物及びコ−テイング製剤 |
JPH02205A (ja) * | 1987-11-09 | 1990-01-05 | Taisho Pharmaceut Co Ltd | 香料含有ソフトカプセル用コーティング剤 |
JPH0641139A (ja) | 1991-09-09 | 1994-02-15 | Sankyo Co Ltd | ヒドロピリジン誘導体 |
JPH0770506A (ja) * | 1993-09-07 | 1995-03-14 | Morishita Roussel Kk | フイルムコーティング組成物およびそれを用いた固形製剤 |
JPH0859512A (ja) * | 1994-08-25 | 1996-03-05 | Morishita Roussel Kk | フィルムコーティング組成物およびそれを用いた固形製剤 |
JPH10310586A (ja) | 1996-06-26 | 1998-11-24 | Sankyo Co Ltd | ヒドロピリジン類の新規医薬用途 |
JP2002145883A (ja) | 2000-07-06 | 2002-05-22 | Sankyo Co Ltd | ヒドロピリジン誘導体酸付加塩 |
JP2002255814A (ja) * | 2000-12-25 | 2002-09-11 | Sankyo Co Ltd | アスピリンを含有する医薬組成物 |
JP2003246735A (ja) | 2001-12-21 | 2003-09-02 | Sankyo Co Ltd | ヒドロピリジン誘導体酸付加塩を含有する医薬 |
JP2004051639A (ja) | 2002-07-18 | 2004-02-19 | Sankyo Co Ltd | 動脈硬化症治療のための医薬組成物 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3784390A (en) * | 1971-07-23 | 1974-01-08 | Hayashibara Biochem Lab | Shaped bodies of pullulan and their use |
US4833617A (en) * | 1987-08-14 | 1989-05-23 | General Electric Company | Solid modeling based adaptive feedrate control for NC machining |
US5015480A (en) * | 1987-11-25 | 1991-05-14 | Eli Lilly And Company | Film coating formulations |
US4931286A (en) * | 1989-04-19 | 1990-06-05 | Aqualon Company | High gloss cellulose tablet coating |
ZA937382B (en) * | 1992-10-06 | 1994-04-29 | Warner Lambert Co | Novel composition for peroral therapy of cognitionimpairment and a process therefor |
JP3583166B2 (ja) * | 1994-06-27 | 2004-10-27 | 興和株式会社 | 損傷皮膚修復用粉末製剤 |
US5542036A (en) * | 1994-07-05 | 1996-07-30 | General Electric Company | Implicit modeling of swept volumes and swept surfaces |
GB9414045D0 (en) * | 1994-07-12 | 1994-08-31 | Berwind Pharma Service | Moisture barrier film coating composition, method, and coated form |
US6044306A (en) * | 1997-10-14 | 2000-03-28 | Vadim Shapiro | Methods and apparatus for shaping moving geometric shapes |
US6099573A (en) * | 1998-04-17 | 2000-08-08 | Sandia Corporation | Method and apparatus for modeling interactions |
GB9901887D0 (en) * | 1999-01-29 | 1999-03-17 | Lightwork Design Ltd | Machining simulation method and apparatus |
US6993461B1 (en) * | 1999-06-10 | 2006-01-31 | Dassault Systemes | Swept volume model |
EP1203580A4 (en) * | 1999-06-18 | 2004-06-30 | Takeda Chemical Industries Ltd | SOLID PREPARATIONS WITH FAST DISINTEGRATION |
US6396492B1 (en) * | 1999-08-06 | 2002-05-28 | Mitsubishi Electric Research Laboratories, Inc | Detail-directed hierarchical distance fields |
DE60110666T2 (de) * | 2000-03-17 | 2006-02-02 | Shin-Etsu Chemical Co., Ltd. | Feste Zubereitung enthaltend niedersubstituierte Hydroxypropylcellulose und Herstellungsverfahren |
KR20090033917A (ko) * | 2000-07-06 | 2009-04-06 | 다이이찌 산쿄 가부시키가이샤 | 히드로피리딘 유도체 산부가염 |
DE60036205T2 (de) * | 2000-07-27 | 2008-05-21 | Roquette Frères | Granulat bestehend aus Stärke und Laktose |
DE60135780D1 (de) * | 2000-12-25 | 2008-10-23 | Daiichi Sankyo Co Ltd | Aspirin enthaltende medizinische zusammensetzungen |
US6724393B2 (en) * | 2001-03-16 | 2004-04-20 | Mitsubishi Electric Research Labs, Inc. | System and method for sculpting digital models |
KR100908418B1 (ko) * | 2001-06-20 | 2009-07-21 | 액티버스 파마 컴퍼니 리미티드 | 퀴놀리논 유도체 의약 조성물 및 그의 제조 방법 |
JP4625204B2 (ja) * | 2001-07-02 | 2011-02-02 | ウチヤ・サーモスタット株式会社 | 安全装置付き電源コード |
DE10144932B4 (de) * | 2001-09-12 | 2014-07-31 | Siemens Aktiengesellschaft | Visualisierung von Werkstücken bei der Simulation von Fräsprozessen |
KR20030065831A (ko) * | 2002-02-01 | 2003-08-09 | 주식회사 태평양 | 사이클로스포린을 함유한 지속 방출형 약학적 조성물 |
CA2493384A1 (en) * | 2002-07-18 | 2004-01-29 | Sankyo Company Limited | Medicinal composition for treating arteriosclerosis |
SI21402A (sl) * | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
US6902609B2 (en) * | 2003-02-20 | 2005-06-07 | Bpsi Holdings, Inc. | Pearlescent film coating systems and substrates coated therewith |
US7042458B2 (en) * | 2003-03-25 | 2006-05-09 | Mitsubishi Electric Research Laboratories, Inc. | Methods for generating an adaptively sampled distance field of an object with specialized cells |
KR20060007385A (ko) * | 2003-04-16 | 2006-01-24 | 교린 세이야꾸 가부시키 가이샤 | 경구 고형 제제 |
EP1660183A2 (en) * | 2003-05-05 | 2006-05-31 | Eli Lilly and Company | Treating cardiovascular diseases with a compound of formula 1 (cs 747 - prasugrel; rn 150322-43-4) |
KR100882156B1 (ko) * | 2003-08-08 | 2009-02-06 | 아지노모토 가부시키가이샤 | 나테글리니드 함유 제제 |
JP5248733B2 (ja) * | 2003-11-28 | 2013-07-31 | エスエス製薬株式会社 | 揮散防止型固形製剤およびその製造方法 |
US9247765B2 (en) * | 2004-01-14 | 2016-02-02 | Omniactive Health Technologies Limited | Stable beadlets of lipophilic nutrients |
TWI367755B (en) * | 2005-05-20 | 2012-07-11 | Sankyo Co | Film coated product |
TWI318571B (en) * | 2005-06-10 | 2009-12-21 | Lilly Co Eli | Formulation of a thienopyridine platelet aggregation inhibitor |
TWI482641B (zh) * | 2006-12-07 | 2015-05-01 | Daiichi Sankyo Co Ltd | 含有低取代度羥丙基纖維素之醫藥組成物 |
TWI428151B (zh) * | 2006-12-07 | 2014-03-01 | Daiichi Sankyo Co Ltd | 含有甘露醇或乳糖之固形製劑 |
US20100280064A1 (en) * | 2006-12-07 | 2010-11-04 | Tomoyuki Watanabe | Pharmaceutical composition having improved storage stability |
US20110104277A1 (en) * | 2009-10-30 | 2011-05-05 | Ma Decheng | Oxygen barrier film coatings for pharmaceutical dosage forms |
-
2007
- 2007-12-06 EP EP07850163A patent/EP2100606A4/en not_active Ceased
- 2007-12-06 CA CA2671975A patent/CA2671975C/en active Active
- 2007-12-06 JP JP2008548325A patent/JPWO2008069262A1/ja active Pending
- 2007-12-06 TW TW096146465A patent/TWI442947B/zh active
- 2007-12-06 WO PCT/JP2007/073547 patent/WO2008069262A1/ja active Application Filing
- 2007-12-06 KR KR1020097011282A patent/KR101665705B1/ko active IP Right Grant
- 2007-12-06 CN CN2007800449606A patent/CN101594863B/zh active Active
- 2007-12-06 US US12/312,969 patent/US20090291138A1/en not_active Abandoned
- 2007-12-06 BR BRPI0719395A patent/BRPI0719395C1/pt active IP Right Grant
- 2007-12-06 CA CA2823981A patent/CA2823981C/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4851777A (ja) * | 1971-10-30 | 1973-07-20 | ||
JPS5942325A (ja) * | 1982-09-03 | 1984-03-08 | Dai Ichi Seiyaku Co Ltd | コ−テイング用組成物及びコ−テイング製剤 |
JPH02205A (ja) * | 1987-11-09 | 1990-01-05 | Taisho Pharmaceut Co Ltd | 香料含有ソフトカプセル用コーティング剤 |
JPH0641139A (ja) | 1991-09-09 | 1994-02-15 | Sankyo Co Ltd | ヒドロピリジン誘導体 |
JPH0770506A (ja) * | 1993-09-07 | 1995-03-14 | Morishita Roussel Kk | フイルムコーティング組成物およびそれを用いた固形製剤 |
JPH0859512A (ja) * | 1994-08-25 | 1996-03-05 | Morishita Roussel Kk | フィルムコーティング組成物およびそれを用いた固形製剤 |
JPH10310586A (ja) | 1996-06-26 | 1998-11-24 | Sankyo Co Ltd | ヒドロピリジン類の新規医薬用途 |
JP2002145883A (ja) | 2000-07-06 | 2002-05-22 | Sankyo Co Ltd | ヒドロピリジン誘導体酸付加塩 |
JP2002255814A (ja) * | 2000-12-25 | 2002-09-11 | Sankyo Co Ltd | アスピリンを含有する医薬組成物 |
JP2003246735A (ja) | 2001-12-21 | 2003-09-02 | Sankyo Co Ltd | ヒドロピリジン誘導体酸付加塩を含有する医薬 |
JP2004051639A (ja) | 2002-07-18 | 2004-02-19 | Sankyo Co Ltd | 動脈硬化症治療のための医薬組成物 |
Non-Patent Citations (4)
Title |
---|
D. CHULIA ET AL.: "Powder Technology and Pharmaceutical Process", 1 December 1993, ELSEVIER SCIENCE PUB CO |
HERBERT A. LIEBERMAN ET AL.: "Pharmaceutical Dosage Forms: Tablets", vol. 1, 1989, MARCEL DEKKER INC. |
LEON LACHMAN ET AL.: "The Theory and Practice of Industrial Pharmacy", 1986, LEA & FEBIGER |
See also references of EP2100606A4 |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9034860B2 (en) | 2006-12-07 | 2015-05-19 | Daiichi Sankyo Company, Limited | Pharmaceutical composition containing low-substituted hydroxypropyl cellulose |
US8900606B2 (en) | 2008-12-25 | 2014-12-02 | Toray Industries, Inc. | Methods of applying coating materials for solid medicines |
US8920818B2 (en) | 2008-12-25 | 2014-12-30 | Toray Industries, Inc. | Coating material for solid medicine and solid medicine formed with same |
WO2010094471A1 (en) * | 2009-02-17 | 2010-08-26 | Krka, D. D., Novo Mesto | Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation |
WO2011015599A1 (de) | 2009-08-07 | 2011-02-10 | Ratiopharm Gmbh | Prasugrel in nicht-kristalliner form und pharmazeutische zusammensetzung davon |
DE102009036646A1 (de) | 2009-08-07 | 2011-02-10 | Ratiopharm Gmbh | Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon |
WO2011052500A1 (ja) * | 2009-10-28 | 2011-05-05 | 第一三共株式会社 | ワックス安定製剤 |
WO2011052499A1 (ja) * | 2009-10-28 | 2011-05-05 | 第一三共株式会社 | 貯蔵安定性が改善された医薬組成物 |
JP5589851B2 (ja) * | 2009-11-30 | 2014-09-17 | 東レ株式会社 | 固形製剤用のフィルムコーティング剤及びこれを用いた固形製剤 |
WO2011065551A1 (ja) * | 2009-11-30 | 2011-06-03 | 東レ株式会社 | 固形製剤用のフィルムコーティング剤及びこれを用いた固形製剤 |
US8980320B2 (en) | 2009-11-30 | 2015-03-17 | Toray Industries, Inc. | Film coating agent for solid preparation, and solid preparation using same |
EP2360159A1 (de) | 2010-02-11 | 2011-08-24 | Ratiopharm GmbH | Prasugrel in mikronisierter, kristalliner Form und pharmazeutische Zusammensetzung davon |
WO2011098536A1 (en) | 2010-02-11 | 2011-08-18 | Ratiopharm Gmbh | Prasugrel in micronized, crystalline form and pharmaceutical composition thereof |
Also Published As
Publication number | Publication date |
---|---|
EP2100606A1 (en) | 2009-09-16 |
CA2823981A1 (en) | 2008-06-12 |
CN101594863B (zh) | 2011-12-07 |
CN101594863A (zh) | 2009-12-02 |
EP2100606A4 (en) | 2009-12-30 |
TW200831141A (en) | 2008-08-01 |
CA2823981C (en) | 2016-05-17 |
BRPI0719395C1 (pt) | 2021-05-25 |
BRPI0719395B8 (pt) | 2020-04-07 |
TWI442947B (zh) | 2014-07-01 |
CA2671975C (en) | 2013-10-29 |
KR101665705B1 (ko) | 2016-10-12 |
BRPI0719395B1 (pt) | 2020-01-21 |
JPWO2008069262A1 (ja) | 2010-03-25 |
KR20090090323A (ko) | 2009-08-25 |
US20090291138A1 (en) | 2009-11-26 |
BRPI0719395A2 (pt) | 2015-03-31 |
CA2671975A1 (en) | 2008-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008069262A1 (ja) | 安定性が改善されたフィルムコーティング製剤 | |
JP5274261B2 (ja) | 低置換度ヒドロキシプロピルセルロースを含有する医薬組成物 | |
WO2008072532A1 (ja) | 貯蔵安定性が改善された医薬組成物 | |
JP5289975B2 (ja) | マンニトール又は乳糖を含有する固形製剤 | |
EP0749308B1 (en) | Film coated tablet of paracetamol and domperidone | |
US20120077980A1 (en) | Method for producing a solid preparation | |
KR101809886B1 (ko) | 소형화된 클래리트로마이신 경구투여 제제 | |
JP2020520892A (ja) | ダビガトランエテキシラート又は医薬的に許容されるその塩を含む錠剤及びその製造方法 | |
JP6858873B2 (ja) | セレコキシブを含む錠剤 | |
WO2003075918A1 (fr) | Comprime contenant du chlorhydrate de pilsicainide (voie humide) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780044960.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07850163 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008548325 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007850163 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097011282 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12312969 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2671975 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: PI0719395 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090528 |